ORGO projects 2026 revenue between $270M and $310M following a 58% year-over-year drop in Q1 net sales.
Organogenesis Holdings forecast 2026 revenue of $270M to $310M as it navigates a prolonged recovery tied to CMS policy impacts. The company reported a 58% year-over-year decline in Q1 net revenue, primarily driven by a 63% drop in Advanced Wound Care product sales.
In Q1, Surgical & Sports Medicine product sales remained flat compared to the prior year. The revenue decline reflects ongoing challenges in the wound care segment, which management attributed to delayed reimbursement adjustments.
No immediate market reaction was disclosed in the earnings call summary.